Reduction of plasma cholesterol by statins is fundamental to prevent coronary heart disease. Such therapy is often sub-optimal, however, particularly in patients with reduced LDL receptors (familial hypercholesterolemia), and novel or adjuvant therapies are therefore warranted. Cholesterol elimination is profoundly influenced by the rate of its conversion to bile acids (BA), regulated by the enzyme Cyp7a1. Induced fecal loss of BA by resin treatment reduces plasma cholesterol, presumably through induction of hepatic LDL receptors (LDLR). We here describe the effect of PR835, a drug belonging to a new class of lipid-lowering agents that inhibit the Slc10a2 protein, the intestinal transporter responsible for active uptake of BA. Treatment reduced plasma cholesterol by 40% in mice devoid of both the LDLR and its ligand, apoE, while triglycerides and HDL cholesterol were unchanged. Cyp7a1 enzyme activity and mRNA were induced several-fold, and hepatic HMG CoA reductase mRNA increased, mirroring an induced synthesis of BA and cholesterol. The addition of a statin potentiated the effect, leading to reductions of plasma total and LDL cholesterol by 64% and 70%, respectively. These effects could not be attributed to induction of other known hepatic lipoprotein receptors and indicate the presence of new points of targeting in lipid-lowering therapy.
resection or biliary fistulation, have been used to derepress Cyp7a1 enzyme activity, increase hepatic LDLR, and thereby stimulate LDL clearance and lower plasma LDL (4, 5) . However, direct stimulation of enzyme activity through Cyp7a1 overexpression or growth hormone treatment has been demonstrated to lower plasma cholesterol also in mice lacking the LDLR (6, 7) . To evaluate the potential for non-LDLR-mediated lipid-lowering by pharmacological stimulation of BA synthesis, we studied LDLR/apoE deficient mice. These animals, which lack both the LDLR and its ligand apoE, display profound hyperlipidemia without dietary manipulations (8) . To specifically inhibit the Slc10a2 protein, we used the drug PR835, a bensothiazepine derivative shown to inhibit taurocholate uptake in cells transfected with human SLC10A2 (9) .
MATERIALS AND METHODS

Mice
Altogether 54 LDLR/apoE deficient female mice (8) were used (M & B, Ry, Denmark). In the dose-response study, animals were 20 weeks old, and in the combination study they were 12 weeks old. All experiments were approved by the local ethical committee for animal experiments.
Drugs
PR835, which was synthesized by Astra Zeneca R&D (Mölndal, Sweden), is a benzothiazepine that inhibits the uptake of taurocholic acid (IC 50 , 0.15 µM) in human cells transfected with SLC10A2 (9) . In vivo, treatment with PR835 inhibits bile acid uptake in mice, and the inhibition of absorption of the bile acid analogue SeHCAT occurs with ED 50 of 0.6 µmol/kg. Atorvastatin (Lipitor R ) was purchased from Warner Lambert Nordics AB (Solna, Sweden).
Treatments
All animals were kept under standardized conditions with free access to water and regular chow (R3, Astra-EWOS, Södertälje, Sweden). The light-cycle hours were between 6:00 a.m. and 6:00 p.m. PR835 was dissolved in PEG/ethanol/solutol/water (4/1/0.5/4, v/v/v/v). PR835 was administered by gavage, at the indicated dose, once a day in the evening for 3 days in the doseresponse study (experiment 1) and for 7 days in experiment 2. The last day, day 4 and 8, respectively, PR835 was administered by gavage in the morning 3 h before killing the animals; the controls received vehicle. Thus in experiment 1, animals received the drug four times; whereas the mice received the drug eight times in experiment 2. In the dose response study, the mice were treated with PR835 (0.6, 2.5, 10, 40 µmol/kg/day). In the combination study, the mice received atorvastatin (0.05% mixed with R3 chow) and PR835 (10 µmol/kg/day).
Tissue collection
Food was removed 3 h before the mice were anesthetized by inhalation of isoflurane, bled by cardiac puncture, and killed by cervical dislocation at 10-11 a.m. Blood plasma was separated and stored at -70°C. Livers and intestines were immediately frozen in liquid nitrogen and stored at -70°C.
Lipid assays
Plasma from each animal was assayed for cholesterol and TG by commercial kits (Roche Diagnostics, GmbH, Germany). Lipoproteins were separated by FPLC (10) and assayed for cholesterol. Quantitation of lipoproteins was performed from the area percentage of the respective lipoprotein class. Free and total cholesterol in liver homogenates and microsomal preparations was determined with the commercial kit after extraction with chloroform/methanol (2:1 v/v).
Assay of 7α-hydroxy-4-cholesten-3-one (C4)
The indicated plasma pools (300 µl) were diluted with saline, and 7β-hydroxy-4-cholesten-3-one was added as internal standard (11) . The samples were extracted, and the eluted product was dried under N 2 and dissolved in acetonitril (HPLC grade, Merck, Darmstadt, Germany) for separation by HPLC (HP 1100 series, Hewlett Packard GmbH, Waldbronn, Germany) at 20°C (mobile phase: acetonitril/water 95/5, 1 ml/min) by using a Nova-Pak C 18 column (part no. WAT011695, Waters Corp., Milford MA). The wavelength was 241 nm.
Cyp7a1 enzymatic activity
Microsomes were prepared from pooled liver samples-three pools per group-and the activity of Cyp7a1 was determined as the formation of 7α-hydroxycholesterol (pmol/mg protein/min) from endogenous microsomal cholesterol by isotope dilution mass spectrometry (12) . Enzyme assays were run in duplicate.
Assays of lipoprotein receptors
Hepatic membranes were prepared from pools of tissue from each group (13), separated on gels under non-reduced conditions, and transferred to filters. LDLR expression was analyzed by using 125 I-labeled rabbit β-VLDL (13). The LDL-receptor bands (~120 kDa) were analyzed by using a Fuji Bio-imaging BAS 1800 analyzer (Fuji Photo Film Co., Tokyo, Japan). LRP, megalin, and VLDL receptor expression was assayed by using RAP (receptor associated protein) and anti-RAP IgG (14). RAP binding was detected by using a chemiluminescence substrate (Supersignal, Pierce, Rockford, IL). To assay SR-BI, indicated amounts of membrane proteins were separated and transferred by using Criterion TM (Bio-Rad Laboratories, Hercules, CA.). The filter was incubated with antibodies specific for SR-BI (1:1500) (Novus Biologicals, Inc., Littleton, CO) and peroxidase conjugated sheep anti-rabbit immunoglobulin (1:10000; The Binding Site Ltd., Birmingham, UK). Chemiluminescence substrate (Supersignal, Pierce, Rockford, IL) was added, and the filters were exposed on X-ray film. Chemiluminescence was determined with a LAS 1000 plus luminescent imager analyzer (Fuji Photo Film). Quantitation of data was performed with Image Gauge software (Science Laboratory 98 ver.3.12, Fuji Photo Film).
Quantitation of mRNA
Total RNA was extracted from frozen samples (RNA stat-60 Tel-Test, Houston, TX) and treated with 6U of RQ1 DNase (Promega, Madison, WI), extracted with phenol:chloroform, 5:1, pH 4.5, (Ambion, Austin, TX), and ethanol-precipitated. RNA (4 µg) were reverse-transcribed by using Superscript II and random hexamers as primers (Life Technologies, Paisley, UK). Relative mRNA levels were determined by using the ABI Prism ® 7700 Sequence Detector (Applied Biosystems, Foster City, CA). TaqMan ® Universal PCR Master Mix (Applied Biosystems) was used, and the samples were quantitated by the delta Ct method by using the acidic ribosomal phosphoprotein PO (36B4) as an internal standard.
The following primer pairs were used Cyp7a1: 5′-CCATGATGCAAAACCTCCAAT-3′ and 5′-ACCCAGACAGCGCTCTTTGA-3′.
HMGR: 5′-AGAATCTTGTGGGCTCGGC-3′and 5′-TTGCTGCGTGGGCGTT-3′.
Slc10a2: 5′-ACCACTTGCTCCACACTGCTT-3′ and 5′ACCCACATCTTGGTGTAGACGA-3′.
I-BABP: 5′-TTTGAGAGTGAGAAGAATTACGATGAGT-3′ and 5′-CGTCCCCTTTCAATCACGTCT-3′.
36B4: 5′-GAGGAATCAGATGAGGATATGGGA-3′ and 5′-AAGCAGGCTGACTTGGTTGC-3′.
The following TaqMan probes were used. 
Statistical analyses
Data are presented as means ± SEM. Differences between groups were tested by one-way ANOVA followed by comparison of group means according to Dunnet's test (Statistica software, Stat Soft, Tulsa, OK).
RESULTS
Effects of PR835 on plasma lipids and on hepatic lipid metabolism
We first determined the effect of increasing doses of PR835, given for 3.5 days, on plasma lipid levels. The treatment did not influence body weight, and the mice did not develop diarrhea. There was a dose-dependent reduction of plasma cholesterol up to 40%, whereas triglycerides (TG) were unaltered (Fig. 1A) . Separation of plasma lipoproteins by FPLC (Fig. 1B and C) showed that the reduction of cholesterol was within chylomicron/VLDL (~60%) and IDL/LDL (~25%) fractions, whereas HDL cholesterol was unaltered.
Cholesterol conversion to BA in the liver is regulated by the activity of cholesterol 7α-hydroxylase (Cyp7a1) (15) . Cyp7a1 transcription is under negative feedback control modulated by the activation of the nuclear BA receptor FXR (16) . Because inhibitors of the Slc10a2 protein should directly diminish the return of BA to the liver, we characterized how treatment with PR835 affected the activity of Cyp7a1 (Fig. 1D ). Both the enzymatic activity and the mRNA levels of Cyp7a1 were increased by PR835 treatment. Stimulation was most pronounced (fourfold) in animals receiving 2.5 µmol/kg/day and tended to decline at higher doses. Analysis of the concentration of 7α-hydroxy-4-cholesten-3-one (C4), a plasma marker that reflects BA synthesis in the liver (17) , confirmed this observation (Fig. 1E) ; also this response was maximal in the group receiving 2.5 µmol/kg/day of PR835. Determination of mRNA for the ratedetermining enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl CoA reductase (HMGR), showed an increase that was also most pronounced in animals receiving this dose (Fig.  1E) . The concentration of free cholesterol in hepatic microsomes was not altered in response to treatment (not shown). Also assay of hepatic total cholesterol and TG confirmed that no significant changes occurred (not shown).
Thus, pronounced reductions of VLDL and LDL cholesterol could be achieved by inhibition of ileal bile acid transport in animals deficient in both the LDLR and its ligand apoE. To screen for other hepatic structures that could explain this unexpected finding, we performed ligand blot analysis by using rabbit 125 I-β-VLDL, which contain apoB-48, apoB-100, and apoE. However, no binding of these lipoproteins could be demonstrated in liver membranes from the treated animals. We also evaluated the expression of other members of the LDLR gene family (18) , such as the LDLR-related protein (LRP), megalin, and the VLDL receptor, by using immunoblot analysis of receptor-associated protein (RAP) binding (14). LRP and megalin were equally abundant in all animals, whereas VLDL receptors were not detectable (not shown). Scavenger receptor B class I (SR-BI) has an important role in HDL metabolism but may also interact with LDL-like particles (19) . Immunoblot analysis of this receptor revealed that it was actually reduced by treatment (Fig. 1F) . The strongest suppression, 50% and 65%, was observed in animals receiving 2.5 and 10 µmol/kg/day of PR835.
Effects of PR835 in combination with atorvastatin on plasma lipids and on hepatic lipid metabolism
Inhibition of the Slc10a2 protein through treatment with PR835 thus stimulated BA synthesis and concomitantly lowered the elevated lipoprotein cholesterol in LDLR/apoE deficient mice. The induction of BA synthesis also resulted in a compensatory increase in HMGR mRNA, indicating a stimulation of hepatic cholesterol synthesis. This response may counteract the lipidlowering ability of the treatment, and we therefore explored the effect of PR835 when used in combination with a potent cholesterol synthesis inhibitor. For this purpose, groups of mice were treated for 7.5 days with PR835, 10 µmol/kg/day, and atorvastatin, 0.05% (w/w), alone or in combination.
Atorvastatin reduced plasma total cholesterol by 25%, whereas PR835 resulted in a 40% reduction ( Fig. 2A) . Combined treatment resulted in a 64% reduction. As previously found, plasma TG were unaltered by PR835 treatment, whereas atorvastatin reduced TG by 60%. Upon combination, plasma TG were reduced by 40% (Fig. 2A) . Lipoprotein separation by FPLC (Fig.  2B and C) showed that atorvastatin reduced cholesterol only in LDL particles (-44%), whereas PR835 reduced both LDL (-30%) and VLDL cholesterol (-62%). The combination of the two drugs resulted in a profound reduction of cholesterol, particularly within LDL particles, which were reduced by 70%. An increase in HDL cholesterol by ~30% was seen after treatment with PR835 alone, whereas atorvastatin treatment resulted in a 20% reduction. The combination did not alter HDL cholesterol.
Atorvastatin and PR835 alone increased Cyp7a1 mRNA levels by 70 and 105%, respectively, whereas the enzymatic activities were increased by 25 and 100%, respectively (Fig. 2D) . Combined treatment strongly increased transcript levels and enzyme activities, by approximately threefold. The effects of treatment on bile acid production, as measured by plasma C4 levels, were somewhat less pronounced (Fig. 2E ). Whereas atorvastatin alone had no effect, PR835 increased C4 by ~40%. As expected, the competitive inhibition of HMGR activity by atorvastatin increased its mRNA by ~13-fold (Fig. 2E) . In agreement with the previous experiment, HMGR mRNA was increased ~2-fold by treatment with only PR835. The hepatic microsomal free cholesterol content was not significantly altered between the groups, although a tendency for reduction (-15%) could be seen in animals receiving the combination.
Screening for
125 I-β-VLDL binding structures by ligand blotting of hepatic membranes did not reveal any binding in this even more extreme situation of lipid-lowering (not shown). Also in this experiment, we were not able to detect any differences in abundance of RAP binding lipoprotein receptors. The expression of SR-BI was confirmed to be reduced following PR835 (Fig. 2F) . SR-BI was suppressed also by atorvastatin treatment, whereas there was no clear additive effect on this receptor when the two drugs were combined.
Effects of PR835 in combination with atorvastatin on Slc10a2 and ileal BA binding protein (I-BABP) mRNA
Finally, we explored the important question of whether inhibition of the Slc10a2 protein would affect its expression in the target tissue, the distal ileum. PR835 alone did not alter the transcript levels of Slc10a2, whereas increases of 30 and 25% were seen after atorvastatin alone and in combination, respectively. The cytosolic ileal BA binding protein (I-BABP) is believed to be involved in the intracellular trafficking of BA, and has been shown to be regulated by the intracellular concentration of BA via FXR (16) . Accordingly, treatment with PR835, alone or in combination with atorvastatin, reduced I-BABP mRNA in distal ileum by 35% (Fig. 2G) . Atorvastatin alone had no effect on I-BABP mRNA.
DISCUSSION
The concept of lowering plasma lipoprotein cholesterol by interruption of the enterohepatic circulation of BA is well established (4). Accordingly, previous studies in which inhibitors of the Slc10a2 protein are used have shown therapeutic effects in mice and rats with diet-induced hyperlipidemia already within 3 days of treatment (20) (21) (22) . As for ileal resection and BA binding resins, this plasma lipid-lowering effect has been linked to an induction of hepatic LDLR (23) . Blocking the compensatory increase in cholesterol synthesis by statins results in a further increase in LDLR, which is believed to explain the additional cholesterol lowering in this situation (4) . The current finding of a drastic reduction of plasma VLDL and LDL cholesterol in response to inhibition of the Slc10a2 protein in animals lacking both the LDLR and apoE is, therefore, quite unexpected. On this moment, we can only speculate on the mechanism(s) responsible for these effects.
One explanation could be that the clearance of lipoproteins, which is profoundly reduced in this animal model (8) , is stimulated by the induction of other mechanisms of hepatic lipoprotein cholesterol uptake than the LDLR. However, by screening liver membranes from treated animals, we could exclude a major role of any of the relevant lipoprotein receptors. The increased catabolism of liver cholesterol induced by treatment could theoretically promote nonreceptor-mediated, apoE-independent uptake of lipoprotein cholesterol from the circulation. However, the degree of stimulation of Cyp7a1 was not always mirrored by the plasma cholesterol. A third explanation could be that the intestinal uptake of dietary and biliary cholesterol is reduced by treatment (21) . Thus, if the increase in synthesis fails to maintain the pool of BA, cholesterol absorption should theoretically be reduced leading to a diminished inflow of chylomicron cholesterol. Assay of the bile acid pool indeed found a ~65% reduction (controls: 57±6.0 and Slc10a2 inhibition 20±2.4 µmol/100 g body weight P<0.05), which was due to a reduction in taurocholic acid and taurobetamuricholic acid. The cholesterol absorption in the current situation was, however, not significantly reduced; controls (72% ± 2.2) and Slc10a2 inhibition (64% ± 4.3) (Gälman, Schreyer et al., unpublished). Finally, the hepatic secretion of VLDL may be reduced by treatment. Thus, in a situation of stimulated BA synthesis, where less hepatic cholesterol may be available, the output of VLDL cholesterol may be reduced. However, free microsomal cholesterol was unaltered. In addition plasma TG levels were not reduced. Further, assay of total hepatic cholesterol and TG confirmed that no significant changes occurred. In humans and primates, VLDL TG secretion is actually enhanced by interruption of BA enterohepatic circulation, and VLDL-TG levels frequently increase (4). A species difference could be related to the relatively much larger flux of VLDL cholesterol in mice compared with humans (24) , which may render mice more sensitive to a reduction of hepatic cholesterol availability. However, FXR inactivation in mice seems to increase VLDL-TG (25) , presumably in part via transcriptional regulation of apo C-II and phospholipid transfer protein (16) . The role of inhibitors of the Slc10a2 protein in the treatment of human hyperlipidemia will be important to explore further.
In conclusion, drugs interfering with BA enterohepatic circulation, such as inhibitors of the Slc10a2 protein, can-particularly in combination with statins-exert profound cholesterol lowering by induction of hepatic Cyp7a1. The fact that this effect can be obtained without induction of hepatic lipoprotein receptors indicates an important potential for targeting BA metabolism in new forms of lipid-lowering therapy. 
